HK Stock Market Move | JACOBIO-B (01167) surged over 6% after positive earnings announcement, achieving profitability for the first time, with expected interim net profit of no less than 600 million yuan.

JACOBIO-B (01167) has surged over 6% following positive earnings news, currently up 6.12% at HKD 5.20, with a trading volume of HKD 1.4392 million. On August 10, JACOBIO-B announced that it expects to achieve a net profit of no less than RMB 600 million for the six months ending June 30, 2026 (the reporting period), compared to a net loss of approximately RMB 58.99 million for the six months ending June 30, 2025. This marks the company's first time achieving profitability. The company's turnaround from a net loss to a net profit during the reporting period is primarily due to significant revenue growth, stemming from contributions including: revenue generated from the global (excluding China (including Hong Kong SAR, Macao SAR, and Taiwan)) strategic licensing collaboration with AstraZeneca AB for JAB-23E73 (pan-KRAS) in research and development, manufacturing, and commercialization; and revenue from the licensing and service agreements signed with Shanghai Allist Pharmaceuticals Co., Ltd. for the research and development, manufacturing, and commercialization of GLECIRASIB (KRAS G12C) and SITNEPROTAFIB (JAB-3312, SHP2) in China.